- 報道写真・映像トップ 報道写真・映像トップ
- 写真・グラフィックス・映像 | 写真・グラフィックス・映像 |
「免疫疾患」の写真・グラフィックス・映像
- 提供元
- 日付
- 種類
- 向き
- カテゴリ
- 色
- 提供元
- 共同通信社 0
- 国内提供元 0
- 海外提供元 0
- 日付
- 24時間以内 0
- 48時間以内 0
- 72時間以内 0
- 7日以内 0
- 30日以内 0
- 1年以内 37
- 期間を指定 41
- 日付指定なし 41
- 種類
- 写真 41
- グラフィックス 0
- 映像 0
- 向き
- 縦 6
- 横 35
- 正方形 0
- カテゴリ
- ニュース
- スポーツ
- エンターテインメント
- 教育向け
- カテゴリ指定なし
- 色
- カラー 41
- モノクロ 0
- 古い順
- 1
- 古い順
本画像はログイン後にご覧いただけます
2021年07月10日MedicationJuly 9, 2021, Memphis, Tennessee, USA: A nurse on disability prepares to take a handful of pills on July 10, 2021in Memphis, Tennessee. The pills have become part of her regiment since she developed medical problems and had to stop working. (Credit Image: © Karen Focht/ZUMA Wire)、クレジット:©Karen Focht/ZUMA Wire/共同通信イメージズ
商品コード: 2021071208729
本画像はログイン後にご覧いただけます
2021年07月10日MedicationJuly 9, 2021, Memphis, Tennessee, USA: A nurse on disability prepares to take a handful of pills on July 10, 2021in Memphis, Tennessee. The pills have become part of her regiment since she developed medical problems and had to stop working. (Credit Image: © Karen Focht/ZUMA Wire)、クレジット:©Karen Focht/ZUMA Wire/共同通信イメージズ
商品コード: 2021071208618
本画像はログイン後にご覧いただけます
2021年07月10日MedicationJuly 9, 2021, Memphis, Tennessee, USA: A nurse on disability prepares to take a handful of pills on July 10, 2021in Memphis, Tennessee. The pills have become part of her regiment since she developed medical problems and had to stop working. (Credit Image: © Karen Focht/ZUMA Wire)、クレジット:©Karen Focht/ZUMA Wire/共同通信イメージズ
商品コード: 2021071208332
本画像はログイン後にご覧いただけます
2021年08月12日Systemic lupus erythematosusSystemic lupus erythematosus (autoimmune disease) with inflammatory skin of the fingers.、クレジット:CAVALLINI JAMES / BSIP/Universal Images Group/共同通信イメージズ
商品コード: 2022082511451
本画像はログイン後にご覧いただけます
2022年09月21日Autoimmune DisorderSeptember 21, 2022, DUBUQUE, IOWA, USA: Carole Schmidt, left undergoes Intravenous immunoglobulin (IVIg) therapy for Immune thrombocytopenia (also known as ITP) at the MercyOne Cancer Center in Dubuque, Iowa. ITP is an autoimmune disorder causing internal bruising and an increased incidence of sometimes life-threatening internal bleeding. Bleeding occurs because the immune system attacks a certain type of cell - platelets - which are needed to help control bleeding. ITP is more common among young women and children. The risk appears to be higher in people who also have diseases such as rheumatoid arthritis, lupus and antiphospholipid syndrome. Research indicates ITP patients often have had a virus or viral infection about three weeks before developing ITP. Scientists believe that the body, when making antibodies against the virus, may have ‘‘accidentally‘‘ made an antibody that sticks to the platelet cells. The body then recognizes these platelet cells with antibodies as foreign cells and destroys them. Th...
商品コード: 2022092703185
本画像はログイン後にご覧いただけます
2022年09月21日Autoimmune DisorderSeptember 21, 2022, DUBUQUE, IOWA, USA: Immune Globulin Intravenous is used in intravenous immunoglobulin therapy (IVIg) to raise blood platelet counts quickly. IVIg is an infusion given with a needle and requires sitting still for some time in an infusion center while the medicine goes into the veins. Most patients with Immune thrombocytopenia (ITP) start with a round of steroids to stop the body from destroying platelets and quickly raise platelet counts. Unfortunately, steroids can also have side effects, such as insomnia, weight gain, and mood changes. Thatââ¬â¢s 1 of the reasons why the American Society of Hematology (ASH) recommends the use of steroids for no more than 6 weeks. (Credit Image: © Kevin E. Schmidt/ZUMA Press Wire)、クレジット:©Kevin E. Schmidt/ZUMA Press Wire/共同通信イメージズ
商品コード: 2022092703152
本画像はログイン後にご覧いただけます
2022年09月21日Autoimmune DisorderSeptember 21, 2022, DUBUQUE, IOWA, USA: Immune Globulin Intravenous is used in intravenous immunoglobulin therapy (IVIg) to raise blood platelet counts quickly. IVIg is an infusion given with a needle and requires sitting still for some time in an infusion center while the medicine goes into the veins. Most patients with Immune thrombocytopenia (ITP) start with a round of steroids to stop the body from destroying platelets and quickly raise platelet counts. Unfortunately, steroids can also have side effects, such as insomnia, weight gain, and mood changes. Thatââ¬â¢s 1 of the reasons why the American Society of Hematology (ASH) recommends the use of steroids for no more than 6 weeks. (Credit Image: © Kevin E. Schmidt/ZUMA Press Wire)、クレジット:©Kevin E. Schmidt/ZUMA Press Wire/共同通信イメージズ
商品コード: 2022092703165
本画像はログイン後にご覧いただけます
2022年09月21日Autoimmune DisorderSeptember 21, 2022, DUBUQUE, IOWA, USA: Immune Globulin Intravenous is used in intravenous immunoglobulin therapy (IVIg) to raise blood platelet counts quickly. IVIg is an infusion given with a needle and requires sitting still for some time in an infusion center while the medicine goes into the veins. Most patients with Immune thrombocytopenia (ITP) start with a round of steroids to stop the body from destroying platelets and quickly raise platelet counts. Unfortunately, steroids can also have side effects, such as insomnia, weight gain, and mood changes. Thatââ¬â¢s 1 of the reasons why the American Society of Hematology (ASH) recommends the use of steroids for no more than 6 weeks. (Credit Image: © Kevin E. Schmidt/ZUMA Press Wire)、クレジット:©Kevin E. Schmidt/ZUMA Press Wire/共同通信イメージズ
商品コード: 2022092703213
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 A man is seen at Pharmasyntez Nord plant before the opening ceremony of the second stage of the plant, in St. Petersburg, Russia. The second stage of the Pharmasyntez-Nord plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040104352
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 President of the Pharmasyntez group of companies Vikram Punia and St. Petersburg Governor Alexander Beglov attend the opening ceremony of the second stage of the plant, in St. Petersburg, Russia. The second stage of the Pharmasyntez-Nord plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040104701
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Director General of the Pharmasyntez Nord company Mikhail Kvasnikov, President of the Pharmasyntez group of companies Vikram Punia and St. Petersburg Governor Alexander Beglov attend the opening ceremony of the second stage of the plant, in St. Petersburg, Russia. The second stage of the Pharmasyntez-Nord plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040104703
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 President of the Pharmasyntez group of companies Vikram Punia and St. Petersburg Governor Alexander Beglov shake hands during the opening ceremony of the second stage of the plant, in St. Petersburg, Russia. The second stage of the Pharmasyntez-Nord plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040104702
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 President of the Pharmasyntez group of companies Vikram Punia and St. Petersburg Governor Alexander Beglov attend the opening ceremony of the second stage of the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040104927
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Director General of the Pharmasyntez-Nord Mikahil Kvasnikov and St. Petersburg Governor Alexander Beglov attend he opening ceremony of the second stage of the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040104925
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Director General of the Pharmasyntez-Nord Mikahil Kvasnikov and St. Petersburg Governor Alexander Beglov shake hands during the opening ceremony of the second stage of the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040104926
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105852
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105857
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105849
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 St. Petersburg Governor Alexander Beglov, accompanied by Director General of the Pharmasyntez Nord company Mikhail Kvasnikov and President of the Pharmasyntez group of companies Vikram Punia, visits the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Anton Vergun / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040104931
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 St. Petersburg Governor Alexander Beglov visits the Pharmasyntez-Nord plant in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040104929
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105839
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 St. Petersburg Governor Alexander Beglov visits the Pharmasyntez-Nord plant in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Anton Vergun / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040104932
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Employees work at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105666
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Employees work at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105835
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105848
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Employees work at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105851
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105836
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105847
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105845
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105838
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Employees work at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105850
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105846
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105841
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Employees work at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105840
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 An employee works at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105837
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Employees work at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105844
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Employees work at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105843
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 Employees work at the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105842
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 St. Petersburg Governor Alexander Beglov attends the opening ceremony of the second stage of the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105879
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 St. Petersburg Governor Alexander Beglov, accompanied by Director General of the Pharmasyntez Nord company Mikhail Kvasnikov attends the opening ceremony Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105877
本画像はログイン後にご覧いただけます
2023年03月30日Russia Pharmaceutical Industry Pharmasyntez Nord30.03.2023 A view shows the Pharmasyntez-Nord plant, in St. Petersburg, Russia. The second stage of the plant will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine. Alexei Danichev / Sputnik、クレジット:Sputnik/共同通信イメージズ
商品コード: 2023040105880
- 1
- 報道写真・映像トップ 報道写真・映像トップ
- 写真・グラフィックス・映像 | 写真・グラフィックス・映像 |